CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Tazemetostatdrug
Likely dose
Tazemetostat 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03456726
NCT03456726Phase 2Completed
CompareCT.gov

A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Eisai Co., Ltd.·interventional·Posted Mar 7, 2018·Updated Dec 16, 2022

In Brief

A Phase 2 clinical trial evaluating Tazemetostat for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. Completed, enrolled 20 participants across 28 sites.

Detailed Summary

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 7, 2018
Enrollment StartApr 9, 2018
Primary CompletionDec 17, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.3 years ago

Interventions

Tazemetostatdrug

Tazemetostat will be provided as a 200 mg oral tablet.